Articles By Jack Cush, MD
Rheumatology Shortage Cliff in Australia & USA
Australia is facing a deepening rheumatology manpower crisis with direct parallels to the situation in the United States.
Read Article
Guselkumab gets FDA Nod for X-ray Protection
The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's supplemental Biologics License (sBLA) to include evidence in the guselkumab (Tremfya) label for the inhibition of progression of structural joint damage in adults with active psoriatic arthritis (PsA).
Read Article
Count Your Telangiectasias (5.29.2026)
Dr. Jack Cush reviews the news, journal articles and missed quiz questions.
Read Article
Increased Polypharmacy in SLE Patients
A cross-sectional study of US adults with systemic lupus erythematosus (SLE) shows significantly increased prevalence of polypharmacy, related to age, disease outcomes and often, non-SLE common medications.
Read Article
Safety of Biologics and Novel Agents
Dr. Jack Cush reviews safety of biologics and novel agents.
Read Article
WSJ: Nurse Practitioner Is Now the Hottest Job in Healthcare
The Wall St. Journal has published a perspective on nurse practitioners (NP) and their very promising careers.
Read Article
RepurpSS-II: Hydroxychloroquine plus Leflunomide in Sjögren's
A small, pilot, phase 2b trial has shown that the combination of leflunomide and hydroxychloroquine (LEF+HCQ) was effective and safe in treating patients with active Sjögren's disease.
Read Article
Trends and Innovations in Lupus Nephritis Clinical Trials
Xu et al. from Shanghai University have written an analysis of global lupus nephritis (LN) clinical trials and call for innovation.
Read Article
Quiz Talk (5.22.2026)
Dr. Jack Cush talks of birthdays, Quizzes and journal articles this week on the podcast.
Read Article
BE BOLD Week 16 data - Bimekizumab vs. Risankizumab in PsA
UCB has released the Week 16 results from BE BOLD trial that will be presented at EULAR 2026 in London on Saturday, June 6.
Read Article